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Summary
Background The presence of pulmonary hyperten-
sion (PH) severely aggravates the clinical course of
heart failure with preserved ejection fraction (HFPEF)
resulting in substantial morbidity and mortality. So
far, neither established heart failure therapies nor pul-
monary vasodilators have proven to be effective for
this condition. Riociguat (Adempas®, BAY 63-2521),
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a stimulator of soluble guanylate cyclase, is a novel
pulmonary and systemic vasodilator that has been
approved for the treatment of precapillary forms of
PH. With regard to postcapillary PH, the DILATE-1
study was a multicenter, double-blind, randomized,
placebo-controlled single-dose study in subjects with
PH associated with HFPEF. Although there was no
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significant change in the primary outcome measure,
peak decrease in mean pulmonary artery pressure
with riociguat versus placebo, riociguat significantly
increased stroke volume without changing heart rate,
pulmonary artery wedge pressure, transpulmonary
pressure gradient or pulmonary vascular resistance.
The present study is designed to test the efficacy of
long-term treatment with riociguat in patients with
PH associated with HFPEF.
Methods/study design The DYNAMIC study is a ran-
domized, double-blind, placebo-controlled, parallel-
group, multicenter clinical phase IIb trial evaluating
the efficacy, safety and kinetics of riociguat in PH-
HFPEF patients. The drug will be given over 26 weeks
to evaluate the effects of riociguat versus placebo.
The primary efficacy variable will be the change from
baseline in cardiac output at rest, measured by right
heart catheter after 26 weeks of study drug treat-
ment. Additional efficacy variables will be changes
from baseline in further hemodynamic parameters,
changes in left and right atrial area, right ventricular
volume, as well as right ventricular ejection fraction
measured by cardiac magnetic resonance imaging,
and changes from baseline in World Health Organiza-
tion (WHO) class and N-terminal prohormone B-type
natriuretic peptide (NT-proBNP).
The trial was registered on 25 August 2014 (EudraCT
Number: 2014-003055-60; www.clinicaltrialsregister.
eu).
Keywords Heart failure with preserved ejection frac-
tion · Pulmonary hypertension · Medical treatment
Abbreviations
CTEPH Chronic thromboembolic pulmonary hy-
pertension
DPG Diastolic pressure gradient
HFPEF Heart failure with preserved ejection frac-
tion
HR Heart rate
IDT Individual dose titration
LVEF Left ventricular ejection fraction
MLHF Minnesota living with heart failure score
PAH Pulmonary arterial hypertension
PAPmean Mean pulmonary artery pressure
PAWP Pulmonary arterial wedge pressure
PH Pulmonary hypertension
PVR Pulmonary vascular resistance
RHC Right heart catheter
SBP Systolic blood pressure
sGC Soluble guanylate cyclase
SVR Systemic vascular resistance
TID Ter in die (three times daily)
TPG Transpulmonary pressure gradient
Background
Nearly half of the patients presenting with symptoms
of heart failure have a normal left ventricular ejection
fraction [1]. This condition is called heart failure with
preserved ejection fraction (HFPEF) and also known
as diastolic heart failure. The major determinant of
mortality in this patient population is coexisting pul-
monary hypertension (PH) [2], classified as group 2.2
in the Dana Point classification [3]. Despite the
frequency and severity of HFPEF, effective medical
treatment is lacking. sRiociguat (Adempas®, BAY 63-
2521), an oral stimulator of soluble guanylate cyclase,
is a novel pulmonary and systemic vasodilator that
has been approved for precapillary forms of PH, e.g.
chronic thromboembolic pulmonary hypertension
(CTEPH) [4] and pulmonary arterial hypertension
(PAH) [5]. Two phase II trials have indicated a po-
tential benefit of riociguat treatment also in patients
with postcapillary PH due to left heart disease. The
phase IIb Left ventricular systolic dysfunction asso-
ciated with pulmonary hypertension riociguat trial
(LEPHT) study was a multicenter, double-blind, ran-
domized, placebo-controlled study in subjects with
PH resulting from heart failure with reduced ejec-
tion fraction (HFREF) [4, 6]. A total of 201 subjects
were randomized to treatment with oral placebo or
riociguat (0.5, 1 or 2 mg TID) for 16 weeks in 4 par-
allel arms. The primary outcome was the placebo-
corrected change from baseline at week 16 in mean
pulmonary artery pressure (PAPmean). Although the
decrease in PAPmean in the riociguat 2 mg group was
not significantly different from placebo, cardiac index
and stroke volume index were significantly increased
without changes in heart rate (HR) or systolic blood
pressure (SBP) compared with placebo. Both pul-
monary and systemic vascular resistance (PVR and
SVR) were significantly reduced with 2 mg riociguat
TID. Riociguat reduced the Minnesota Living with
Heart Failure (MLHF) score.
The proof of concept study DILATE-1 was a multi-
center, double-blind, randomized, placebo-controlled
single-dose study in subjects with PH associated
with HFPEF [7]. Clinically stable subjects with a left
ventricular ejection fraction (LVEF) >50%, PAPmean
≥25 mm Hg and pulmonary arterial wedge pressure
(PAWP) >15 mm Hg at rest were randomized to single
oral doses of placebo or riociguat. There were no sig-
nificant changes in peak decrease in PAPmean with ri-
ociguat 2 mg versus placebo; however, riociguat 2 mg
significantly increased stroke volume and decreased
SBP and right ventricular end-diastolic area, without
significantly changing HR, PAWP, the transpulmonary
pressure gradient (TPG) and PVR. Based on the re-
sults of the single-dose DILATE-1 study in PH-HFPEF
patients and the LEPHT study over 16 weeks in sub-
jects with PH-HFREF, the present study is expected to
generate data to assess the therapeutic potential of
riociguat in PH-HFPEF.
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Fig. 1 Schemeof up-
titration regimen in theDY-
NAMICstudy. TID3 times
aday, v studyvisit. aup-




The DYNAMIC study is a randomized, double-blind,
placebo-controlled, parallel-group, multicenter clin-
ical phase IIb trial evaluating the hemodynamic ef-
fects, safety, and kinetics of riociguat in PH-HFPEF
patients. The study drug will be administered over
26 weeks to evaluate the effects of riociguat versus
placebo. Written informed consent will be obtained
from patients in accordance with the Declaration of
Helsinki and the ethics committee of the Medical
University of Vienna has approved the study protocol
(date of vote: 10-OCT-2014; reference number: EK
1570/2014).
Titration and treatment phases
After a pretreatment phase of up to 4 weeks, the study
phase will consist of an 8-week (up-)titration phase
followed by the 18-week fixed-dose treatment. Pa-
tients will be randomized to the active treatment arm
or placebo. The starting dose of riociguat will be
0.5 mg 3 times a day (TID). At visits 2 and 3 (weeks 2
and 4), up-titration to a dose of 1.0 and 1.5 mg TID
(Fig. 1) is based on clinical condition and systemic
SBP, measured before intake of the next study drug
dose in accordance with the following algorithm:
During the titration phase in the first 8 weeks, the
dose for the next titration step will depend on the SBP
measured at trough before intake of the next study
drug dose. The following algorithm applies to the in-
dividual dose titration (IDT) scheme:
● If trough SBP is ≥110 mmHg, increase the dose.
● If trough SBP is between 100 and 109 mm Hg with-
out symptoms of hypotension, maintain the dose.
● If trough SBP is <100 mm Hg without symptoms of
hypotension, reduce the dose.
The IDT scheme is based on blood pressure and con-
sideration of the subject’s clinical condition; there-
fore, in cases of poor tolerability, a planned up-titra-
tion step may be postponed and the dose maintained.
During the 18-week treatment phase (from visit 3 to
visit 6), all patients will receive the dose of visit 3. Dose
reductions or interruptions for safety reasons are al-
lowed at any time.
Selected patient enrolment criteria
Eligible patients will be aged 18–80 years at the time of
informed consent and have symptomatic PH-HFPEF,
e.g. group 2/2.2 of the Dana Point classification [3]
and World Health Organization (WHO) class II to IV,
defined as:
● LVEF ≥50%, diagnosed by echocardiography or left
heart catheterization (LHC) within 30 days before
randomization,
● PAPmean ≥25 mm Hg at rest, measured by right
heart catheter (RHC) within 12 weeks before ran-
domization,
● PAWP >15 mm Hg at rest, measured by RHC within
12 weeks before randomization.
The dose regimen of the background treatment must
have been stable for >30 days before randomization.
Diuretic therapy must have been stable for ≥1 week.
Selected exclusion criteria are listed in Table 1.
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Table 1 Selectedexclusioncriteria
Cardiac decompensation, either with hospitalization or visit to the emergency department ≤30 days before randomization
Resynchronization therapy
Need of IV diuretics ≤30 days before randomization
Treatment with IV inotropes or IV vasodilators≤30 days before randomization
Chronic treatment with ERAs, PDE-5 inhibitors or prostanoids ≤30 days before randomization or with nitrates or PDE-5 inhibitors indicated for erectile dysfunc-
tion ≤7 days before randomization
Bronchial asthma or COPD with FEV1 <60 % of predicted
Restrictive lung disease with TLC <60 % of predicted
Current O2 therapy
Clinically relevant hepatic dysfunction indicated by either AST ≥3 times the upper limit of normal or Child-Pugh stage B and C in patients with cirrhosis
Severe renal impairment (glomerular filtration rate <30 ml/min/1.73 m2 calculated by the Modification of Diet in Renal Disease formula)
Uncontrolled arterial hypertension (SBP >180 mm Hg or DBP >110 mm Hg)
SBP <100 mm Hg at baseline or clinical signs or symptoms of hypotension
Myocardial disease, such as infiltrative myocardial disease (i. e. amyloidosis, hypertrophic cardiomyopathy)
Severe aortic or mitral stenosis or regurgitation or any valvular stenosis or regurgitation with indications for surgery
Coronary artery disease with angina of Canadian Cardiovascular Society class III or IV or requiring nitrates
Unstable angina or acute myocardial infarction <90 days before randomization
Reperfusion procedure (PCI or coronary artery bypass graft) <90 days prior to randomization or <3 weeks in case of a negative stress test after PCI
Stroke with persistent neurological deficits or known hemodynamically relevant symptomatic carotid artery stenosis
Resting heart rate while awake of <50 BPM or >105 BPM or in the case of AF >110 BPM
IV indicates intravenous, ERAs endothelin receptor antagonists, PDE-5 phosphodiesterase-5, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory
volume in 1 s, TLC total lung capacity, O2 oxygen, AST aspartate transaminase, SBP systolic blood pressure, DBP diastolic blood pressure, PCI percutaneous
coronary intervention, BPM beats per minute, AF atrial fibrillation
Study objectives
The primary objective of this study is to assess the
pharmacodynamic profile of riociguat in subjects with
symptomatic PH-HFPEF. The secondary objectives of
this study are to assess changes in dimensions of left
and right ventricles and cardiac function parameters
using cardiac magnetic resonance imaging (CMRI).
Patients with a PVR above and below 240 dyn×s×cm–5
will be analyzed as prespecified subgroups.
Primary efficacy variable
The primary efficacy variable is the change from base-
line of cardiac output (CO) at rest, measured by RHC
after 26 weeks of study drug treatment.
Secondary efficacy variables
● Change from baseline in left and right atrial area,
right ventricular volume and right ventricular ejec-
tion fraction, measured by CMRI
● Change from baseline in PVR, SVR, TPG and PAWP,
measured by RHC
● Change from baseline in WHO class
● Change from baseline in serum N-terminal prohor-
mone B-type natriuretic peptide (NTproBNP) levels
Exploratory efficacy variables
● Change from baseline in all other CMRI parameters
not listed above. At selected sites only: T1 mapping
and extracellular volume (ECV).
● Change from baseline in all other RHC parameters
not listed under secondary variables.
● Change from baseline in echocardiography param-
eters, including left ventricular end-diastolic and
end-systolic volumes, tricuspid annular plan sys-
tolic excursion, pressure gradient of tricuspid valve,
diameter of inferior vena cava, respiratory collapsi-
bility of inferior vena cava, mitral peak velocity of
early (E) and late (A) filling, E-wave deceleration
time, LVEF, estimate of mean right atrial pressure,
systolic pulmonary artery pressure and E/A ratio.
● Change from baseline in exercise capacity (6 min
walk distance) and in Borg CR 10 scale.
● Change from baseline in quality of life scores Euro-
Qol five dimensions questionnaire (EQ-5D), MLHF.
● Events of special interest considered for calculation
of the combined endpoint time to clinical worsen-
ing.
● All-cause mortality.
● Composite endpoint as defined by time to death
from cardiovascular causes or first hospitalization
for a cardiovascular event, including acute or wors-
ening heart failure, acute myocardial infarction,
stroke or ventricular arrhythmia.
● Change in glomerular filtration rate.
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Pharmacokinetics
To investigate drug exposure and potential relation-
ships to drug effects, plasma concentrations of rio-
ciguat and its main metabolite M-1 (BAY 60-4552)
will be determined. Plasma concentrations will be
measured using a validated high performance liquid
chromatography-mass spectrometry/tandem mass
spectrometry (HPLC-MS/MS) method. Quality con-
trol (QC) and calibration samples will be analyzed
concurrently with study samples. The results of QC
samples will be reported together with concentrations
in unknown samples in the clinical study report.
Statistical considerations
Statistical analyses will be performed using Statisti-
cal Analysis Software (SAS®). A randomized subject
will be valid for safety analysis if at least one dose of
study drug was administered. A subject will be part
of the full analysis set (FAS) in accordance to the In-
ternational Conference on Harmonization (ICH) E9
guideline, if he/she belongs to the safety set, is not
violating any major entry criteria and shows any post-
baseline efficacy data. A subject will be valid for the
per-protocol analysis if the subject belongs to FAS and
does not show any major protocol deviations that in-
terfere with the interpretation of efficacy results. All
variables will be analyzed descriptively with appropri-
ate statistical methods: categorical variables by fre-
quency tables and continuous variables by sample
statistics (e.g. number of non-missing data, mean,
standard deviation, minimum, median, quartiles and
maximum).
The primary efficacy variable will be submitted to
an analysis of covariance (ANCOVA) model including
the baseline value as covariate, center, treatment reg-
imen and the interaction term of center by treatment
regimen as fixed effects. If the treatment-center in-
teraction is not significant at the 0.2 level, the inter-
action term will be removed from the model for final
analysis. The primary comparison will be a one-sided
test at the 2.5% significance level for the difference in
treatment effects between riociguat and placebo.
Continuous secondary endpoints will be analyzed
in the same manner as the primary endpoint. The
change of WHO class will be dichotomized by defin-
ing the groups: “improvement by at least one class”,
“no improvement by at least one class” and analyzed
using Mantel-Haenszel weights stratified by center.
The secondary efficacy variables will be tested in ex-
ploratory manner at nominal one-sided significance
level of 2.5%.
Determination of sample size
Requiring an 80% power of the trial to detect a mean
difference of at least 0.6 l/min between riociguat and
placebo with regard to the primary endpoint and as-
suming a standard deviation of 1.0 l/min, which is
derived from a previous trial (LEPHT), then 45 evalu-
able subjects are needed in each of the 2 treatment
groups. Taking into account a drop-out rate of 20%,
a total of 114 subjects are to be randomized (57 sub-
jects per group).
Discussion
The DYNAMIC study is the first randomized, double-
blind, placebo-controlled, multi-center trial testing
the effects of an oral soluble guanylate cyclase (sGC)
stimulator targeting PH due to HFPEF. The results
will potentially be of great clinical relevance given the
high prevalence of PH among patients with HFPEF
and its influence on morbidity and mortality.
Pulmonary vasodilators in heart failure with
preserved ejection fraction
Pulmonary vasodilators have previously been stud-
ied in only few clinical trials, which have yielded
conflicting results. In a placebo-controlled, sin-
gle center clinical study in PH-HFPEF patients, the
phosphodiesterase-5 inhibitor sildenafil lowered pul-
monary artery pressure and improved right ventric-
ular function [8]. By contrast, sildenafil failed to
improve endpoints in a cohort of HFPEF patients
without significant PH [9]. In the RELAX trial [9]
peak O2 consumption was not changed in the treat-
ment arm as compared with placebo. Secondary
endpoints including change in 6 min walking dis-
tance, composite clinical status score and change in
quality of life at 24 weeks were also missed. More-
over, subgroup analysis showed no improvement in
peak O2 consumption in patients with higher pul-
monary artery systolic pressure where the median
was 41 mm Hg (range 32–51 mm Hg) in the treatment
group.
Currently, two additional multicenter, placebo-con-
trolled clinical trials testing the effects of pulmonary
vasodilators in HFPEF are underway. The SOCRATES
PRESERVED program was designed to study the ef-
fects of the novel once-daily oral sGC stimulator veri-
ciguat (BAY 1021189) in a phase II dose-finding study
among patients with HFPEF stabilized after hospi-
talization or i. v. diuretic therapy for worsening of
chronic heart failure [10]. Although the DYNAMIC
study follows a similar study rationale that is based
on systemic vasoreactivity and potential cardiac ef-
fects of the sGC stimulator, main differences with re-
spect to SOCRATES PRESERVED are the patient popu-
lation under investigation (HFPEF versus PH-HFPEF)
and main study endpoints (change in NT-proBNP and
left atrial volume at 12 weeks versus invasively mea-
sured CO at 26 weeks).
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The MELODY study, which has recently been rolled
out, focuses on the effects of macitentan, a novel
dual endothelin receptor blocker versus placebo in
a rare subpopulation of PH-HFPEF patients, which
are characterized by elevated pulmonary diastolic
pressure gradients indicative of true pulmonary vas-
cular remodelling on top of elevated left-sided filling
pressures; however, there is cumulating evidence that
the use of riociguat in patients with PH associated
with heart failure is most effective in the subgroup
with a PVR <240 dyn ×s ×cm–5 [11]. Given the un-
certainties regarding the optimal target population,
i. e. pure postcapillary versus combined precapillary
and postcapillary PH, the current protocol will be
open for a broad range of hemodynamic profiles of
patients fulfilling the diagnostic criteria of postcapil-
lary PH.
Rationale for the long-term use of riociguat in
pulmonary hypertension due to heart failure with
preserved ejection fraction
Riociguat is a direct oral sGC stimulator [12] that tar-
gets reduced nitric oxide (NO) bioavailability in PH as
well as in heart failure. Riociguat stimulates the en-
zymatic activity of sGC to generate cyclic guanosine
monophosphate (cGMP) both independently of NO
and synergistically with NO, and is a potent, dose-de-
pendent vasodilator [13]. Beyond its hemodynamic
effects, riociguat reduced renal and cardiac fibrosis,
increased creatinine clearance, decreased atrial natri-
uretic peptide and left ventricular mass in two inde-
pendent models of hypertension [14].
More recently, the beneficial effect of riociguat
on hemodynamic and clinical endpoints has been
demonstrated in three placebo-controlled trials. Ri-
ociguat significantly improved exercise capacity and
secondary efficacy endpoints in the phase III Pul-
monary Arterial Hypertension Soluble Guanylate Cy-
clase-Stimulator Trial (PATENT) [5] and the Chronic
Thromboembolic Pulmonary Hypertension Soluble
Guanylate Cyclase-Stimulator Trial (CHEST) [4]. In
a randomized, placebo-controlled phase IIb study
in patients with heart failure and PH due to systolic
left ventricular dysfunction (LEPHT) [4], riociguat
was well-tolerated and improved the cardiac index,
PVR and SVR, as well as quality of life, without sig-
nificantly changing PAPmean (primary endpoint)
or SBP.
Taken together, the efficacy of long-term treatment
with riociguat has been demonstrated in precapillary
as well as postcapillary PH. Given similar pathophys-
iological changes, such as elevation in left ventricular
filling pressures (LEPHT) [4] and PVR (PATENT and
CHEST) [4, 5] in PH-HFPEF, we speculate that previ-
ously observed beneficial effects of riociguat on pul-
monary and systemic vascular trees as well as cardiac
function will also occur in PH-HFPEF. This is sup-
ported by recently published results from the DILATE-
1 (Acute Hemodynamic Effects of Riociguat in Patients
with Pulmonary Hypertension Associated with Dias-
tolic Heart Failure [7]) study, a multicenter, placebo-
controlled phase IIa trial that tested safety and efficacy
of single oral doses of riociguat (0.5, 1.0 or 2.0 mg) in
PH-HFPEF. There was no significant change in peak
decrease in PAPmean (primary endpoint) with 2 mg
riociguat versus placebo; however, 2 mg riociguat sig-
nificantly increased stroke volume and decreased SBP
and right ventricular end-diastolic area, without sig-
nificantly changing heart rate, PAWP, TPG or PVR. Im-
portantly, riociguat was well tolerated.
Change in cardiac output as primary endpoint
The primary objective of the present study is to test
the effects of riociguat on the surrogate endpoint CO.
While CO is one of the established therapy response
markers in PH [3], therapeutic interventions that lead
to an increase in CO in left heart disease are under
debate. While an increase in CO based on a posi-
tive inotropic effect results in elevated left ventricular
filling pressures and increased mortality [15], in the
LEPHT study [4], which was conducted in heart failure
patients, riociguat significantly improved CO in the
absence of any significant change in heart rate or SBP
compared with placebo. Most importantly, left ven-
tricular filling pressures remained unchanged without
excess mortality and clinical benefit was supported
by an improvement in quality of life. The mecha-
nisms underlying the observed increase in CO in the
LEPHT study are complex. Improvements were not
attributable to reflex sympathetic activation elicited
by a decrease in SBP. The rise in cardiac function was
paralleled by a decrease in PVR and SVR. The potential
of direct sGC stimulators in heart failure might go be-
yond hemodynamic effects and additionally, or even
predominantly, rely on non-hemodynamic effects of
sGC-derived cGMP signalling in a variety of tissues
including cardiac myocytes [16]. Furthermore, pre-
clinical data suggest that sGC stimulation does not in-
crease cyclic adenosine monophosphate (cAMP) pro-
duction despite significant cGMP increases and may
blunt the inotropic response to adrenergic stimulation
[17, 18]. In the DILATE-1 study a pronounced effect
of riociguat on CO was observed accompanied by size
reduction of the right ventricle. These data provide
a strong rationale for CO as a primary endpoint in
PH-HFPEF patients.
Cardiac magnetic resonance imaging substudy
Patients in all centers will undergo a CMRI study.
Studies will consist of functional and late gadolinium
enhancement (LGE) imaging, according to standard
protocols [19]. In the Vienna subgroup T1 map-
ping sequences [20] will be used for the quantifi-
cation of ECV in the left ventricular myocardium.
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This technique has been developed for character-
ization and quantification of subtle diffuse my-
ocardial fibrosis [20]. In light of potential direct,
non-hemodynamic effects of riociguat on the myo-
cardium, this substudy may provide insights into
alternative mechanisms of action.
Conclusion
● Based on experiences from the DILATE-1, LEPHT,
PATENT and CHEST trials, the DYNAMIC study
adds innovative principles to a phase II drug devel-
opment program in PH-HFPEF.
● Given the previously reported pharmacodynamic
activity of the novel drug class of oral sGC stimula-
tors in patients with heart failure and patients with
PH, the study design provides the groundwork for
a subsequent phase III pivotal trial in patients with
PH-HFPEF.
Open access funding provided by Medical University of
Vienna.
Conflict of interest J.Mascherbauer has received fees and re-
search grants from Bayer Healthcare, AOP Orphan, Actelion,
Pfizer and Novartis. E. Grünig is member of the national and
international advisory boards of Bayer HealthCare, Novartis,
Actelion, Pfizer, GlaxoSmithKline and has received financial
compensation for talks by Bayer HealthCare, Novartis, Acte-
lion, Pfizer, United Therapeutics, Gilead and GlaxoSmithK-
line. M. Halank has received fees for board memberships
(Actelion, Bayer andNovartis), lectures (Actelion, Bayer, GSK,
Novartis, OMT andPfizer), travel, accommodation andmeet-
ing expenses (Actelion, Bayer, GSK and Novartis) I.M. Lang
is member of the speakers’ bureau of Actelion, Bayer, Astra
Zeneca, Servier and is recipient of research grants from Acte-
lion, Bayer, AOP Orphan and United Therapeutics. R. Frey is
a former employee of Bayer Pharma involved in the develop-
ment of riociguat and holds stocks in Bayer. D. Bonderman
has received fees and research grants from Bayer Health-
care, AOP Orphan, United Therapeutics, Actelion, Pfizer
and Novartis. W. Hohenforst-Schmidt, A.A. Kammerlander,
I. Pretsch, R. Steringer-Mascherbauer S. Ulrich and M. War-
genau declare that they have no competing interests.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC
guidelines for the diagnosis and treatment of acute and
chronic heart failure 2012: the task force for the diagnosis
and treatment of acute and chronic heart failure 2012
of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association (HFA) of
theESC.EurHeartJ.2012;33:1787–847.
2. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT,
RedfieldMM.Pulmonaryhypertensioninheartfailurewith
preserved ejection fraction: a community-based study.
JAmCollCardiol. 2009;53:1119–26.
3. GalieN, HoeperMM,HumbertM, et al. Guidelines for the
diagnosis and treatment of pulmonary hypertension: the
task force for the diagnosis and treatment of pulmonary
hypertension of the European Society of Cardiology (ESC)
and the European Respiratory Society (ERS), endorsed by
theInternationalSocietyofHeartandLungTransplantation
(ISHLT).EurHeartJ.2009;30:2493–537.
4. Bonderman D, Ghio S, Felix SB, et al. Riociguat for pa-
tientswithpulmonaryhypertensioncausedby systolic left
ventricular dysfunction: a phase IIb double-blind, ran-
domized,placebo-controlled,dose-ranginghemodynamic
study. Circulation. 2013;128:502–11.
5. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for
the treatment of pulmonary arterial hypertension. NEngl
JMed. 2013;369:330–40.
6. GhioS,BondermanD,FelixSB,etal. Leftventricularsystolic
dysfunction associated with Pulmonary Hypertension
riociguat Trial (LEPHT): rationale and design. Eur J Heart
Fail. 2012;14:946–53.
7. BondermanD, Pretsch I, Steringer-Mascherbauer R, et al.
Acute hemoDynamic effects of rIociguat in patients with
puLmonary hypertension Associated with diasTolic heart
failurE(DILATE-1)): a randomized,double-blind,placebo-
controlled, single-dose study. Chest. 2014;146(5) doi:10.
1378/chest.14-0106.
8. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary
hypertension in heart failure with preserved ejection
fraction: a target of phosphodiesterase-5 inhibition in
a1-yearstudy. Circulation. 2011;124:164–74.
9. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phos-
phodiesterase-5inhibitiononexercisecapacityandclinical
status in heart failure with preserved ejection fraction:
arandomizedclinical trial. JAMA.2013;309:1268–77.
10. PieskeB,Butler J,FilippatosG,etal. Rationaleanddesignof
the SOluble guanylate Cyclase stimulatoR in heArT failurE
Studies (SOCRATES). Eur J Heart Fail. 2014;16(9) doi:10.
1002/ejhf.135.
11. Bonderman D, Ghio S, Felix SB, et al. Riociguat for heart
failurewith secondarypulmonaryhypertension: post-hoc
analysisof theLEPHTstudy. EurHeartJSuppl. 2014;35:385
12. StaschJP,EvgenovOV.Solubleguanylatecyclasestimulators
in pulmonary hypertension. Handb Exp Pharmacol.
2013;218:279–313.
13. StaschJP,BeckerEM,Alonso-AlijaC,etal. NO-independent
regulatory site on soluble guanylate cyclase. Nature.
2001;410:212–5.
14. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-
independent stimulation of soluble guanylate cyclase
reducesorgandamageinexperimental low-reninandhigh-
reninmodels. JHypertens. 2010;28:1666–75.
15. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral
milrinone on mortality in severe chronic heart failure.
The PROMISE Study Research Group. N Engl J Med.
1991;325:1468–75.
16. Paulus WJ, Tschope C. A novel paradigm for heart failure




17. Cawley SM, Kolodziej S, Ichinose F, Brouckaert P, Buys ES,
Bloch KD. sGC{alpha}1 mediates the negative inotropic
effects ofNO in cardiacmyocytes independent of changes
in calcium handling. Am J Physiol Heart Circ Physiol.
2011;301:H157–H163.
888 Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and. . . K
original article
18. Ramos-Espiritu LS, Hess KC, Buck J, Levin LR. The soluble
guanylyl cyclase activator YC-1 increases intracellular
cGMP and cAMP via independent mechanisms in INS-1E
cells. JPharmacolExpTher. 2011;338:925–31.
19. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E.
Standardized cardiovascular magnetic resonance (CMR)
protocols 2013 update. J Cardiovasc Magn Reson.
2013;15:91.
20. Moon JC, Messroghli DR, Kellman P, et al. Myocardial
T1 mapping and extracellular volume quantification:
a Society for CardiovascularMagnetic Resonance (SCMR)
and CMR Working Group of the European Society of
Cardiology consensus statement. J Cardiovasc Magn
Reson. 2013;15:92.
K Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and. . . 889
